Bendamustine Hydrochloride

盐酸苯达莫司汀

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameBendamustine Hydrochloride
Drug Alias Namebendamustine宾达氮芥盐酸宾达dabendamustinabendamustinum +[25] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA cross linking agents
TargetsDNA
Therapy Area/IndicationsBrain metastasesSolid tumoursMyelodysplastic Syndromes +[25] 
Global Approved IndicationsLymphoma, Mantle-CellLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 
Approved Indications in ChinaLymphoma, B-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2008/03/20
Country/TerritoryCanadaUnited StatesSlovakia +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSymbio LlcCephalon
China Registration ClassN/A

Develop Information

Active CompaniesSymbio LlcSwiss Cancer InstitutePharmaand GmbH +[9] 
Inactive CompaniesMundipharma Research LtdOtto Von Guericke University MagdeburgSharp Corp +[25] 
Active IndicationsLymphoma, Mantle-CellLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 
Inactive IndicationsBrain metastasesSolid tumoursMyelodysplastic Syndromes +[20] 

Other Information

ATC CodeL01AA09
Related LinksWikipediaDrugBankKEGG